



国内版

国际版

TYMS/KRAS/BRAF Molecular Profiling Predicts Survival Following Adjuvant Chemc



All

Images

Videos

翻译成中文

关闭取词

27,100 Results

Any time ▾

## Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) › Journal List › Scientific Reports

Dec 22, 2015 · **Mutations** in genes such as **KRAS**, **NRAS**, **BRAF** and **PIK3CA** have become an important part of **colorectal carcinoma** evaluation. The aim of this study was to screen for mutations in these genes in Chinese patients with **colorectal cancer** (CRC) and to explore their correlations with certain clinicopathological parameters.

Cited by: 25

Author: Jing Zhang, Jianming Zheng, Yinghong Y...

Publish Year: 2016

## Targeting BRAF in metastatic colorectal cancer: Maximizing ...

<https://www.sciencedirect.com/science/article/pii/S0305737217301299>

**Molecular** and clinical pathogenesis and presentation. **BRAF mutations** develop via the serrated/methylated pathway, which is characterized by the CpG island methylator phenotype (CIMP). CIMP-high (CIMP-H) tumors are characterized by abnormally high levels of genomic methylation in cancer tissue compared with normal tissue (Fig. 1) [6], [23].

Cited by: 12

Author: John H. Strickler, Christina Wu, Tanios Be...

Publish Year: 2017

## Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA ...

[www.nature.com](http://www.nature.com) › scientific reports

Dec 22, 2015 · Introduction. In addition to **KRAS** mutations, mutations in other downstream effectors of the EGFR signaling pathway, such as **BRAF**, **NRAS**, and components of the PI3K signaling pathway, potentially exert negative effects on the response to **anti-EGFR** antibodies 9,10,11,12,13,14.

Cited by: 25

Author: Jing Zhang, Jianming Zheng, Yinghong Y...

Publish Year: 2016



**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Invited Manuscript ID:** 47100

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Study*

**TYMS/KRAS/BRAF molecular profiling predicts survival following  
adjuvant chemotherapy in colorectal cancer**

Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas,  
Georgia Vourli, George Peros, Iordanis Papadopoulos, Ioannis Panayiotides,  
Anna Koumarianou

Match Overview

1	Internet 108 words crawled on 28-Sep-2017 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	3%
2	Internet 24 words crawled on 13-May-2019 <a href="http://rd.springer.com">rd.springer.com</a>	1%
3	Internet 17 words crawled on 03-Dec-2018 <a href="http://cslide.ctimeetingtech.com">cslide.ctimeetingtech.com</a>	<1%
4	Internet 15 words crawled on 01-Apr-2019 <a href="http://www.jcancer.org">www.jcancer.org</a>	<1%





国内版

国际版

TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemot



All

Images

Videos

翻译成中文

关闭取词

28,000 Results

Any time ▼

### Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687048>

Dec 22, 2015 · Mutations in genes such as **KRAS**, **NRAS**, **BRAF** and **PIK3CA** have become an important part of **colorectal carcinoma evaluation**. The aim of this study was to screen for mutations in these genes in Chinese patients with **colorectal cancer** (CRC) and to explore their correlations with certain clinicopathological parameters.

**Cited by:** 27**Author:** Jing Zhang, Jianming Zheng, Yinghong Yan...**Publish Year:** 2016

### MicroRNA profiling predicts survival in anti-EGFR treated ...

<https://www.sciencedirect.com/science/article/pii/S2210776212002293>

MicroRNA **profiling predicts survival** in anti-EGFR treated chemorefractory metastatic **colorectal cancer** patients with wild-type **KRAS** and **BRAF** Author links open overlay panel Neda Mosakhani a Leo Lahti b Ioana Borze a Marja-Liisa Karjalainen-Lindsberg a Jari Sundström c Raija Ristamäki d Pia Österlund e Sakari Knuutila a Virinder Kaur Sarhadi a

**Cited by:** 58**Author:** Neda Mosakhani, Leo Lahti, Ioana Borze, M...**Publish Year:** 2012

### Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA ...

<https://www.nature.com/articles/srep18678>

Dec 22, 2015 · Introduction. In addition to **KRAS mutations**, mutations in other downstream effectors of the EGFR signaling pathway, such as **BRAF**, **NRAS**, and components of the PI3K signaling pathway, potentially exert negative effects on the response to **anti-EGFR antibodies** 9,10,11,12,13,14.

**Cited by:** 27**Author:** Jing Zhang, Jianming Zheng, Yinghong Yan...**Publish Year:** 2016**Author:** Jing Zhang

### Effectors of Epidermal Growth Factor Receptor Pathway: The ...

[journals.plos.org/plosone/article?id=10.1371/journal.pone.0081628](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0081628) ▼

The program for the **PCR amplification** in **KRAS**, **BRAF**, **NRAS** and **PIK3CA** exon20 was as **follows**: 1 min of **initial denaturation** at 95°C, 35 cycles of amplification consisting of 30 s at 94°C, 40 s at 57°C, and 30 s at 72°C, with a final additional elongation at 72°C for 7 min.

**Cited by:** 76**Author:** Yinchun Shen, Jianfei Wang, Xiaohong Han...